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Abstract: Several mesoporous silica nanoparticle (MSN) contrast agents have been 
synthesized using a co-condensation method to incorporate two different Gd3+ complexes 
at very high loadings (15.5–28.8 wt %). These MSN contrast agents, with an MCM-41 type 
pore structure, were characterized using a variety of methods including SEM and TEM, 
nitrogen adsorption measurements, thermogravimetric analysis (TGA), direct current 
plasma (DCP) spectroscopy, and powder X-ray diffraction (PXRD). The magnetic resonance 
(MR) relaxivities of these contrast agents were determined using a 3 T MR scanner. The r1 
relaxivities of these nanoparticles range from 4.1 to 8.4 mM−1s−1 on a per Gd basis. 
Additionally, the MSN particles were functionalized with an organic fluorophore and 
cancer cell targeting peptide to allow for demonstration of both the optical and MR contrast 
enhancing capabilities in vitro. 










Contrast-enhanced magnetic resonance imaging (MRI) is a noninvasive diagnostic technique 
capable of providing high resolution anatomical images of soft tissue as well as giving quantitative 
assessment of disease pathogenesis [1–3]. Currently used MRI contrast agents are either small 
molecule gadolinium(III) chelates or simple manganese(II) molecules that are administered in high 
doses. Small molecule MRI contrast agents currently used in the clinic often cannot provide 
sufficient image contrast enhancement in early disease stages owing to their lack of sensitivity. 
Nanoparticle-based MR contrast agents are much more sensitive owing to the enhanced relaxivity 
on per magnetic center basis as a result of reduced tumbling rates and large payloads of active 
magnetic centers. Superparamagnetic iron oxide nanoparticles have for example been used as 
efficient T2 contrast agents to image tumor angiogenesis, inflammation, and gene expression [4–6]. 
Gd3+-containing microemulsions and other lipid particles have on the other hand been shown to be 
efficient T1-contrast agents for in vivo MR imaging [7]. Several other Gd
3+-containing solid 
nanoparticles have also been recently evaluated as potential MRI contrast agents [8–19]. 
We have previously developed a solid silica nanoparticle based MRI contrast agent, which 
consists of 37 nm particles coated with either a monolayer coating or a polymeric multilayer 
coating of Gd3+ chelates [11]. The results from these two systems revealed that the particles with a 
multilayer coating had reduced efficiency, or lower relaxivities, on a per Gd3+ basis. This was due 
to the fact that the Gd chelates on the inner layers were not as accessible to the surrounding water 
molecules [11]. The need for the magnetic centers to be highly accessible to water molecules 
prompted us to develop new strategies for synthesizing highly efficient nanoparticulate T1 contrast 
agents. In order to increase the number of metal centers per particle without reducing the water 
accessibility of the metal centers, we developed an alternative method for forming the nanoparticulate 
contrast agents via a layer-by-layer electrostatic self-assembly process [12]. Up to 7 bilayers of 
alternating cationic Gd(III)-DOTA oligomer and negatively charged polystyrenesulfonate were 
assembled onto solid silica nanoparticles containing a monolayer of negatively charged Gd 
chelates. The MR relaxivity on a per Gd basis remained constant, independent of the number of 
layers assembled. As a result, the relaxivity on a per particle basis increased linearly with the 
increasing number of layers deposited. We attributed the enhanced MR relaxivity to the highly 
disordered structure of the layer-by-layer assembly which allows for efficient interaction of all the 
Gd(III) centers with the surrounding water. 
Porous nanostructures represent an alternative platform for incorporating a large number of Gd 
chelates while keeping them all accessible to the surrounding water. Mesoporous silica materials 
exhibit high surface areas and tunable pore structures and therefore provide an ideal platform for 
the development of MR-enhancing hybrid materials. MCM-41 type materials, for example, possess 
a hexagonal array of one dimensional channels with diameters that can be tuned from 2 nm to  
10 nm [20,21]. More recently, synthetic procedures have been developed for controlling the 
morphologies of MCM-41 materials [22,23], leading to mesoporous silica nanospheres (MSNs) 
with diameters ranging from 20 to 1,100 nm [24–26]. Such hybrid nanomaterials have already been 
demonstrated in a variety of applications including catalysis [27–30] and drug delivery [31–39]. We 
recently designed a highly efficient nanoparticulate MR contrast agent by grafting Gd chelates 




onto MSNs and demonstrated their utility in MR imaging [40]. The loading of Gd chelates in the 
previously reported MSN system is, however, limited by the grafting efficiency.  
In order to further increase the payload of Gd chelates on MSNs, we expored an alternative 
synthetic strategy based on a co-condesation procedure that was previously reported to be capable 
of incorporating various organic functional groups into the pores of MSNs [41,42]. In this paper 
we report the synthesis of mesoporous silica nanoparticles with co-condensed Gd(III) chelates and 
their applications as optical and MR contrast agents in vitro. Two silyl-derived Gd complexes were 
directly incorporated during the nanoparticle synthesis at different loadings, and the MR contrast 
enhancing abilities were evaluated. The co-condensation procedure affords MSNs with much 
higher loadings of Gd(III) chelates, but the r1 relaxivities of these nanoparticles appear to be 
smaller than previously reported MSNs with grafted Gd(III) chelates on a per Gd basis, presumably 
owing to the reduced accessibility of the Gd(III) chelates to the water molecules. A silyl-derived 
organic fluorophore and targeting agent were also grafted to the surface to allow for target-specific 
optical and MR imaging of cancer cells. 
2. Results and Discussion  
2.1. Synthesis 
Two diethylenetriamine pentaacetic acid (DTPA) based ligands were synthesized in this work. The 
first ligand, 3-aminopropyl(trimethoxysilyl)-diethylenetriamine tetraacetic acid (Si-DTTA), was 
synthesized by reacting 3-(trimethoxysilylpropyl)diethylene triamine with 4 equivalents of bromoacetic 
acid under basic conditions. This formed a Gd chelating ligand containing one trialkoxy silane 
functional group for attachment to the silica based particles. The second ligand, bis(3-aminopropyl 
triethoxysilyl)-diethylenetriamine pentaacetic acid (Si2-DTPA) was synthesized by reacting 2 equivalents 
of 3-aminopropyltriethoxysilane with DTPA dianhydride in anhydrous pyridine. This provided a Gd 
chelating ligand with two trialkoxysilane functional groups to allow for incorporation into the 
mesoporous silica. The corresponding Gd(III) complexes for each ligand were formed by reacting 1 
equivalent of GdCl3 with the deprotonated form of the ligand. The Gd(III) complexes of Si-DTTA and 
Si2-DTPA are denoted Gd-1 and Gd-2, respectively. 
Several MSN-Gd contrast agents were synthesized by incorporating varying amounts of the  
Si-DTTA-Gd (Gd-1) or Si2-DTPA-Gd (Gd-2) complexes into the particles using a co-condensation 
method (Scheme 1). Particles were synthesized using 10 wt % Gd-1 (1) and 10, 20, 30, and 40 wt % 
Gd-2 complexes (2–5) (relative to the amount of TEOS added), using a base-catalyzed condensation 
reaction. For example, particles of 2 (with 10 wt % Gd-2 in the feed) were synthesized by 
simultaneously adding TEOS (0.93 g, 4.48 mmol) and Gd-2 (0.130 g, 0.134 mmol) to a mixture of 
CTAB (0.20 g, 0.55 mmol) and 0.7 mL of 2 M NaOH (1.40 mmol) in 240 mL of water at 80 °C. The 
reaction mixture was then stirred at 80 °C for 2 h. The particles were isolated by centrifuging and 
washed with water and ethanol. The surfactant template was then extracted with a 1 wt % solution of 
NaCl in methanol at room temperature. In order to ensure the removal of any free Gd3+ ions, the 
particles were also washed with a pH = 3 solution. 
  




Scheme 1. Surfactant template synthesis of mesoporous silica nanoparticles (MSN) 1–5. 
 
2.2. Characterization 
Scanning electron and transmission electron microscopies (SEM and TEM) were used to evaluate 
the particle size and morphology. The particles ranged in size from approximately 75 nm to several 
hundred nanometers, with the size generally increasing with increasing wt % of the Gd complex 
(Figure 1). The SEM and TEM images also showed some evidence of slight aggregation and fusing. 
Figure 1. SEM and TEM images of MSN samples 1 (a,b), 2 (c,d), and 3 (e,f). SEM images 
of MSN samples 4 (g) and 5 (h). 
 
TGA was used to characterize the amount of Gd chelate that had been incorporated in each of the 
products from the co-condensation reactions (Figure 2 and Figures S1–S4). After extraction of the 
surfactant, the weight loss in the 230–450 °C temperature range corresponds to the organic portion of 
the incorporated Gd complexes. The precise amount of Gd complex that had been incorporated was 
then determined by measuring the [Gd] of a digested particle solution using direct current plasma 
(DCP) spectroscopy. The TGA and DCP gave fairly consistent results as to the amount of incorporated 
Gd complex (Table 1). The amount of the incorporated Gd(III) chelates tracks fairly well with that in 
the feed, but appears to reach a maximum loading at ~30 wt %. 
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Table 1. Determination of incorporated Gd(III) complexes (wt %) in MSNs by TGA 
and DCP. 
Particles 
Gd complex in 
the feed (wt %) 
Incorporated Gd 




complex by DCP 
1 Gd-1 (10) 16.0 5.3 15.2 
2 Gd-2 (10) 15.5 3.8 15.1 
3 Gd-2 (20) 23.1 4.7 18.7 
4 Gd-2 (30) 27.7 6.8 26.8 
5 Gd-2 (40) 28.8 8.1 32 
Figure 2. TGA of 2 before (black) and after (red) surfactant extraction. 
 
The pore structure of the particles was evaluated using powder X-ray diffraction (PXRD) and 
nitrogen gas sorption measurements. Pristine MCM-41 particles synthesized in our lab exhibit PXRD 
peaks at 2θ values of 2.8°, 4.6°, and 5.4° that are characteristic of the (100), (110), and (200) planes of 
the MCM-41 material, respectively. PXRD of the co-condensed samples shows a similar pattern, 
although the peak is much broader indicating less defined pore structure (Figure S5). Nitrogen gas 
sorption measurements indicated that the surfactant-extracted MSN particles are highly porous with 
BJH (Barrett-Joiner-Halenda) surface areas ranging from 149 to 1674 m2/g and have pore diameters 
ranging from 1.4 to 2.9 nm (Figure 3 and Figures S6–S13). The surface areas and pore sizes decrease 
with increasing incorporation of Gd-2 (Table 2).  
Table 2. Summary of Barrett-Joiner-Halenda (BJH) surface areas and pore sizes. 
Particle 




Pore size  
(nm) 
1 Gd-1 (10) 832 1.94 
2 Gd-2 (10) 1674 2.91 
3 Gd-2 (20) 1095 2.75 
4 Gd-2 (30) 923 2.46 





















Figure 3. Nitrogen sorption isotherm for 2. The inset shows the pore size distribution. 
Black color represents adsorption and green color represents desorption data.  
The relaxivities for the particles were measured using a 3 T MR scanner. The r1 values ranged from 
4.1 to 8.4 mM−1s−1, and the r2 values ranged from 16.1 to 32.7 mM
−1s−1 (Figure 4 and Figures S14–S17). 
The relaxivities for these particles were generally lower than what was obtained for our previously 
published MSN systems that were grafted with Gd(III) chelates post-synthetically  
(r1 = 28.8 mM
−1s−1 and r2 = 65.5 mM
−1s−1 at 3 T) [40]. There was relatively little difference in the per 
Gd relaxivities across samples with varying amounts of incorporated Gd complex (Table 3). The lower 
relaxivity values for the co-condensed samples may be due to the fact that some of the Gd chelates that 
were incorporated into the particles are not at the surface, and therefore are not available to undergo 
water exchange with the solvent. The relaxivities of these particles, however, compare favorably to the 
small molecule contrast agent Magnevist, which has an r1 value of 4.1 mM
−1s−1 under the same 
conditions [9]. 
Figure 4. r1 (blue) and r2 (red) relaxivity curves of 2 measured at 3 T. 
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Table 3. Summary of relaxivities measured at 3 T. 
Particles r1 (mM−1s−1) r2 (mM−1s−1) 
1 6.2 32.7 
2 5.1 16.1 
3 4.1 25.3 
4 4.8 22.9 
5 8.4 25.6 
2.3. In Vitro Experiments 
For in vitro experiments, particles 4 were tagged with an organic fluorophore to enable visualization 
of the particles using confocal microscopy. The particles were also made target specific by grafting an 
RGD peptide onto the surface. This peptide sequence targets the αvβ3 integrin, which is over expressed 
on many types of cancer cells [43]. 
Figure 5. Overlaid DIC and Fluorescence Image of HT-29 colon cancer cells incubated 
with no MSN (left), 500 μg MSN (center), or 500 μg MSN-RGD (4a) (right). All scale bars 
indicate 25 μm. 
 
Laser scanning confocal fluorescence microscopy images indicated the localization of the 
nanoparticles on the surface of the HT-29 human colorectal adenocarcinoma cells after 30 min of 
incubation (Figure 5 and Figure S18). The cells incubated with no particle (Figure 5, left) showed no 
rhodamine fluorescence, while the cells incubated with particles showed significant fluorescence. 
Addition of the cRGD peptide did not appear to induce internalization of the nanoparticles through 
receptor mediated endocytosis, but did increase localization of the particles on the cell surface. 
MRI imaging on a 9.4T scanner showed that the nanoparticles gave T2-weighted enhancement of 
HT-29 cells incubated with nanoparticles 4 for 1 h (Figure 6). The pronounced T2-weighted 
enhancement is expected given the much higher r2/r1 ratios for these MSN particles than the previously 
reported MSNs with post-synthetically grafted Gd(III) chelates [40]. Cells incubated with nanoparticles 
showed increased T2-weighted contrast compared to the control. In addition, cells incubated with the 
targeted nanoparticles displayed enhanced T2-weighted contrast compared to cells incubated with the 
non-targeted nanoparticles. The in vivo utility of the present co-condensed MSN nanoparticles is, 
however, limited due to their relatively large sizes and non-degradable nature. The particles cannot be 




cleared from the kidney, and as the particles stay in the organs for an extended period of time, the 
leaching of toxic Gd3+ ions from the particles becomes a significant concern. 
Figure 6. T2 Weighted MRI image (9.4T) of HT-29 cells incubated with no MSN (right), 
300 µg MSN (4) (center), and 300 µg MSN-RGD (4a) (left). 
 
3. Experimental Section 
Cetyltrimethylammonium bromide (CTAB), GdCl3·6H2O, bromoacetic acid, and tetraethyl 
orthosilicate (TEOS) were purchased from Aldrich and used without further purification.  
3-(trimethoxysilylpropyl)diethylene triamine, (3-isocyanatopropyl)triethoxysilane, and  
3-aminopropyltriethoxysilane were purchased from Gelest. All other chemicals were purchased from 
Fisher Scientific and used without further purification. Thermogravimetric analysis (TGA) was 
performed under air using a Shimadzu TGA-50 equipped with a platinum pan at a heating rate of 3 °C 
per minute. Powder X-ray diffraction (PXRD) patterns were collected on a Bruker SMART APEX II 
diffractometer using Cu radiation. The PXRD patterns were processed with the APEX 2 package using 
the phase ID plug-in. A Hitachi 4700 field emission scanning electron microscope (SEM) and a JEM 
100CX-II transmission electron microscope (TEM) were used to determine particle size and 
morphology. A Cressington 108 Auto Sputter Coater equipped with a Au/Pd (80/20) target and an 
MTM-10 thickness monitor was used to coat the samples with a 5 nm thick conductive layer before 
taking SEM images. Each SEM sample was prepared by suspending the nanoparticles in ethanol.  
A drop of the suspension was then placed on a glass slide and the solvent was allowed to evaporate. 
TEM samples were also prepared from ethanolic particle dispersions on amorphous carbon coated 
copper grids. An Applied Research Laboratories (ARL) SpectraSpan 7 DCP spectrometer was used to 
measure Gd3+ concentrations. 
Synthesis of 3-aminopropyl(trimethoxysilyl)-diethylenetriamine tetraacetic acid (Si-DTTA). 
Bromoacetic acid (0.5558 g, 4.00 mmol) and 3-(trimethoxysilylpropyl)-diethylene triamine (0.2654 g, 
1.00 mmol) were dissolved in 1.0 mL of distilled water and 2.0 mL 2 M sodium hydroxide (4.00 mmol) 
with magnetic stirring. The reaction mixture was subsequently heated to 50 °C, and an additional  
3.0 mL of 2 M NaOH was added dropwise over approximately 30 min. After stirring for an additional 
2 h at 50 °C, the solvent was removed under reduced pressure to yield a viscous yellow oil. An off-
white hygroscopic powder was isolated from the oil in high yield (>90%) by precipitation with ethanol 
and subsequent drying under vacuum. MS (ESI negative ion): m/z 542.2 [M-H]− for the  
silanetriol from a basic solution. NMR: 1H (D2O, 300 MHz): δ 0.47 (2H), 1.55 (2H), 2.62–2.78 (10H), 
3.14–3.21 (8H). 




Synthesis of Si-DTTA-Gd Complex (Gd-1). The gadolinium complex was prepared by dissolving 
the isolated Si-DTTA product (108.6 mg, 0.2 mmol) in 4 mL of distilled water with magnetic stirring 
at room temperature. GdCl3 (380 μL of a 0.50 M solution, 0.19 mmol) was slowly titrated into the 
solution while maintaining a pH of ~9 with the dropwise addition of 2 M NaOH. The reaction was then 
stirred at room temperature for an additional 2 h. The resultant solution was used directly. 
Synthesis of Bis(3-aminopropyl triethoxysilyl)-diethylenetriamine pentaacetic acid (Si2-DTPA). 
Diethylenetriamine pentaacetic acid dianhydride (5.000 g, 13.995 mmol) was dissolved in 110 mL of 
anhydrous pyridine under a steady flow of nitrogen. Using standard Schlenk line techniques  
3-aminopropyl triethoxysilane (6.85 g, 31.00 mmol) was added and the resultant reaction mixture was 
magnetically stirred under nitrogen for 24 h. The product was then precipitated with copious amounts 
of hexane, isolated via centrifuging, washed with additional aliquots of hexanes, and dried to yield 
10.436 g (93.2 %) of the desired compound (Si2-DTPA). MS (ESI negative ion): m/z 631.3  
[M-H]− for the silanetriol from a basic solution. NMR: 1H (DMSO-d6): δ 0.52 (t, 4H), 1.14 (t, 18H), 
1.44(p, 4H), 2.81 (t, 4H), 2.92 (t, 4H), 3.04 (q, 4H), 3.22 (s, 6H), 3.34 (s, 4H), 3.73 (q, 12H), 8.06  
(t, 2H). 13C{1H} (DMSO-d6): δ 8.0, 18.8, 23.4, 41.8, 51.2, 52.8, 55.9, 56.7, 58.3, 58.4, 170.7, 173.4. 
Synthesis of Si2-DTPA-Gd Complex (Gd-2). To prepare the gadolinium complex, Si2-DTPA  
(1.77 g, 2.22 mmol) was dissolved in ~3 equivalents of NaOH (6.0 mL of a 1.0 M solution) with 
magnetic stirring for 30 min. To this solution was added 0.90 equivalent of GdCl3 (4.0 mL of a  
0.5 M solution, 0.002 mol) and the mixture was magnetically stirred at room temperature for several 
hours, the volume of the solution was adjusted to 10 mL to yield a visibly clear yellow 0.20 M solution 
of the modified gadodiamide complex. 
Synthesis of co-condensed MSN with 10 wt % Gd-1 in the feed (1). 0.04 g (0.11 mmol) of 
CTAB was dissolved in 48 mL of H2O containing 0.14 mL of 2 M NaOH (0.28 mmol). The solution 
was heated to 80 °C. After reaching 80 °C, 0.2 mL of TEOS, and 2.54 mL (0.036 mmol) of a 0.014 M 
aqueous solution of Gd-1 were then added. The reaction was then stirred for an additional 2 h at 80 °C. 
The product was isolated by centrifuging, and washed with water, acidic water (pH = 3), and ethanol. 
The surfactant was extracted (3 times) using 1 wt % NaCl in methanol. Yield: 32.9 mg. 
Synthesis of co-condensed MSN with 10 wt % Gd-2 in the feed (2). 0.20 g (0.55 mmol) of 
CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH (1.4 mmol). The solution 
was heated to 80 °C. After reaching 80 °C, 1.0 mL of TEOS, and 0.79 mL (0.134 mmol) of a 0.17 M 
aqueous solution of Gd-2 were then added. The reaction was then stirred for an additional 2 h at 80 °C. 
The product was isolated by centrifuging, and washed with water, acidic water (pH = 3), and ethanol. 
The surfactant was extracted using the same procedure as above. Yield: 150.1 mg.  
Synthesis of co-condensed MSN with 20 wt % Gd-2 in the feed (3). 0.20 g (0.549 mmol) of 
CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH (1.40 mmol). The solution 
was heated to 80 °C. After reaching 80 °C, 1.0 mL of TEOS, and 1.37 mL (0.233 mmol) of a 0.17 M 
aqueous solution of Gd-2 were then added. The reaction was then stirred for an additional 2 h at 80 °C. 
The product was isolated by centrifuging, and washed with water, acidic water (pH = 3), and ethanol. 
The surfactant was extracted using the same procedure as above. Yield: 326.1 mg.  
Synthesis of co-condensed MSN with 30 wt % Gd-2 in the feed (4). 0.20 g (0.549 mmol) of 
CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH (1.40 mmol). The solution 
was heated to 80 °C. After reaching 80 °C, 1.0 mL of TEOS, and 2.04 mL (0.347 mmol) of a 0.17 M 




aqueous solution of Gd-2 were then added. The reaction was then stirred for an additional 2 h at 80 °C. 
The product was isolated by centrifuging, and washed with water, acidic water (pH = 3), and ethanol. 
The surfactant was extracted using the same procedure as above. Yield: 241.0 mg.  
Synthesis of co-condensed MSN with 40 wt % Gd-2 in the feed (5). 0.220 g (0.603 mmol) of 
CTAB was dissolved in 240 mL of H2O containing 0.70 mL of 2 M NaOH (1.40 mmol). The solution 
was heated to 80 °C. After reaching 80 °C, 1.0 mL of TEOS, and 3.03 mL (0.455 mmol) of a 0.15 M 
aqueous solution of Gd-2 were then added. The reaction was then stirred for an additional 2 h at 80 °C. 
The product was isolated by centrifuging, and washed with water, acidic water (pH = 3), and ethanol. 
The surfactant was extracted using the same procedure as above. Yield: 276.3 mg.  
Synthesis of Rhodamine-APS. 6.8 mg (0.0127 mmol) of rhodamine B isothiocyanate was 
dissolved in 1.1 mL of ethanol. 3.3 µL (3.1 mg, 0.0141 mmol) of 3-aminopropyltriethoxysilane was 
then added, and the reaction was stirred at room temperature, under N2, and in the dark for 24 h. At the 
completion of the reaction the solution was diluted to a total volume of 2 mL with additional ethanol to 
make a solution with a rhodamine-APS concentration of approximately 6 mM. 
Synthesis of tri(ethoxy)silylpropyl carbamoyl c(RGDfK). Cyclic(RGDfK) (2.0 mg, 3.313 μmol) 
was placed in a small round bottom flask and dried under high vacuum for 1 h. The c(RGDfK) was 
then dissolved in 0.5 mL of anhydrous DMSO and 0.2 μL of Hünig base. 0.86 μL (3.44 μmol) of  
(3-isocyanatopropyl)triethoxysilane was then added, and the reaction was stirred under argon for 18 h. 
The solution (4 mg c(RGDfK)/mL DMSO) was placed in a freezer for later use. 
Rhodamine B and RGD functionalized MSN (4a). 46 mL of ethanol was placed in a round 
bottom flask, and 1.2 mL of NH4OH (3 vol%) was added. 4 mL of a 5 mg/mL suspension of 4 was 
then added followed by 200 µL of a 4 mg/mL solution of Si-c(RGDfK) and 66 µL of a 6 mM solution 
of rhodamine-APS. The reaction was then stirred at room temperature, in the dark, for 18 h. The 
particles were then isolated by centrifuged at 10,000 rpm for 10 min, and were washed with water and 
ethanol before being redispersed in ethanol. 
Relaxivity Measurements. MR relaxivities were determined on a Siemens 3 T Allegra (Siemens 
Medical Systems, Erlangen, Germany) with a CP head coil. A 3D FLASH sequence was utilized to 
compute T1 maps with seven different flip angles (2°, 5°, 10°, 20°, 30°, 40°, and 60°). Imaging 
parameters were: FOV = 190 × 190 × 64 mm3, Matrix size = 128 × 128 × 32, TR/TE = 40/1.64 ms, 
total data acquisition time was 19 min. A 2-D multiple echo spin echo sequence was used to estimate 
T2 maps. In total, 32 echoes with an echo spacing of 6.2 ms were obtained. The first echo time was  
6.2 ms. TR was 3,000 ms. FOV and matrix size were set to 190×190 mm2 and 128×128. The slice 
thickness was 2 mm. The total data acquisition time was about 6 min and 29 seconds. 
Confocal microscopic and MRI imaging. HT-29 colon adenocarcinoma (ATCC Number:  
HTB-38) were cultured in McCoy’s 5A (Cellgro, Manassas, VA, USA) supplemented with 10% Fetal 
Bovine Serum (Aldrich, St. Louis, MO, USA), 200IU penicillin, and 200 μg streptomycin (Cellgro). 
Cells were incubated at 37 °C with 5% CO2.  
HT-29 cells were collected by trypsinization and were diluted to 300,000 cells/mL with McCoy’s 
5A media. One mL of the suspension was placed on a glass coverslip in the center of a six well cell 
plate. Three mL of cell media was then added around the suspension and the plate was incubated for 
24 h. The plate was removed from the incubator and the media was removed, washed once with PBS 
and replaced with 3 mL fresh media. At this point, 500 μg of nanoparticles (1 mL media) were added. 




The plate was then incubated for an additional 30 min. The plate was removed, the wells washed twice 
with PBS and 1 mL fresh media was added. The coverslips were removed from the wells and imaged 
at the microscopy services laboratory of the Department of Pathology and Laboratory Medicine at  
UNC-Chapel Hill. An Olympus FV500 Confocal Laser Scanning Microscope was used with DIC 
settings. The RITC tagged nanoparticles were imaged using 543 nm excitation and a 560 nm long pass 
emission filter.  
HT-29 cells were plated in 25 cm3 T-necked flasks at 3.3 million cells/flask in 7 mL media  
(3 flasks). The flasks were returned to the incubator overnight. The next day, the flasks were 
removed from the incubator. The media was removed from the flask, washed once with PBS, and  
5 mL fresh media was added. Each flask then received either 0.3 mg of non-targeted nanoparticle, 
0.3 mg of targeted nanoparticle, or no nanoparticle in 0.5 mL PBS. The flasks were returned to the 
incubator for 1 h. The media was then removed from each flask, washed thrice with PBS, and  
2 mL of trypsin-EDTA was added to each flask to detach the cell monolayers. The flasks were 
returned to the incubator for 10 min. The cells were then isolated by centrifugation and redispersed into 
200 μL PBS. The cells were re-pelleted in PCR tubes and imaged on a 9.4 T scanner at the Small 
Animal Imaging Facility at UNC-CH. 
4. Conclusions 
We have designed and characterized several hybrid mesoporous silica nanospheres (MSN-Gd) with 
strong ability to enhance MR images. Two different Gd chelates were incorporated into MSN particles 
with the MCM-41 type pore structure using a co-condensation method. The present co-condensation 
procedure affords much higher loadings of Gd(III) chelates, and the MR relaxivities of these 
nanoparticles on a per Gd basis appear to be larger than the small molecule Gd(III) chelates. The utility 
of the mesoporous silica nanospheres with co-condensed Gd(III) chelates as contrast agents for optical 
and MR imaging has been demonstrated in vitro.  
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